CARDIOVASCULAR DEVICE SALES TO QUADRUPLE, TOP $7 BILLION BY 2000, PACED BY IMPLANTABLES.MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Supported by an aging population and new products, U.S. sales of implantable and interventional cardiovascular devices will quadruple quad·ru·ple adj. 1. Consisting of four parts or members. 2. Four times as much in size, strength, number, or amount. 3. Music Having four beats to the measure. n. from $1.86 billion in 1993 to $7.5 billion in the year 2000, growing at a 22 percent compound annual rate, projects a new study just released by Frost & Sullivan. Implantable devices will lead growth, expanding their already dominant share of the combined market from 71 percent in 1993 to 88 percent in 2000 while that of interventional devices correspondingly dips from 29 to 12 percent, forecasts the report, U.S. IMPLANTABLE AND INTERVENTIONAL CARDIOVASCULAR DEVICE MARKETS: INCREASED COMPETITION WITHIN A $1.86 BILLION INDUSTRY. Implantable defibrillators and left-ventricular assist devices that provide therapy for life-threatening conditions including congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. and tachycardia tachycardia: see arrhythmia. tachycardia Heart rate over 100 (as high as 240) beats per minute. When it is a normal response to exercise or stress, it is no danger to healthy people, but when it originates elsewhere, it is an arrhythmia. will contribute particularly to growth. While the demographics The attributes of people in a particular geographic area. Used for marketing purposes, population, ethnic origins, religion, spoken language, income and age range are examples of demographic data. of an aging population will favor overall market growth, price erosion will worsen wors·en tr. & intr.v. wors·ened, wors·en·ing, wors·ens To make or become worse. worsen Verb to make or become worse worsening adjn as healthcare industry cost-consciousness intensifies price competition. The relationship between the industry and both Medicare and third- party private health insurance agencies is growing more difficult with new cost-cutting pressure. Escalating healthcare costs and the resulting push for cost- containment have changed healthcare institution buying patterns and thus the way manufacturers market. Shifts in hospital decision- making are taking power away from physicians, who increasingly have to account for their choice of devices. Buying decisions are shifting to administrators. Manufacturers are increasingly expected to provide cost-benefit resource- utilization data as a marketing tool. Federal regulatory requirements Regulatory requirements are part of the process of drug discovery and drug development. Regulatory requirements describe what is necessary for a new drug to be approved for marketing in any particular country. have also tightened, with multi-center randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. trial data now required before rather than after device approval, making severe budgetary demands on smaller R&D companies. These changes mean longer waiting periods before approvals are received and firms can generate revenues to recover costs of device development. The industry is focusing heavily on developing less invasive devices. As procedures made possible by current and new devices grow less traumatic, the expanding elderly population will see shorter hospital stays and lower healthcare costs. Another trend is toward designing devices that are more user- friendly and easier to manipulate to maximize their clinical usefulness. A key example is implantable pacemakers Pacemakers Definition A pacemaker is a surgically-implanted electronic device that regulates a slow or erratic heartbeat. Purpose Pacemakers are implanted to regulate irregular contractions of the heart (arrhythmia). , whose expanded programming capabilities are currently under-utilized. As such products have been enhanced with new features and greater microprocessing capabilities, they have become more complex to operate, discouraging full realization of their therapeutic potential. Frost & Sullivan is an international high-technology research firm. All Frost & Sullivan reports are based on extensive interviews with marketing and technical experts from selected companies in each market segment. Primary research is validated val·i·date tr.v. val·i·dat·ed, val·i·dat·ing, val·i·dates 1. To declare or make legally valid. 2. To mark with an indication of official sanction. 3. by thorough analysis of available secondary research. Frost & Sullivan is the leading publisher worldwide of high-technology research reports. Report: 5084-54 Publication Date: 1994 Price: $2295 Total Implantable and Interventional Cardiovascular Device Market: Revenue Forecasts (U.S.), 1990-2000 Revenue Revenues Growth Year ($ BIL BIL Brother-In-Law BIL Billion BIL Bilateral BIL Band Interleaved by Line BIL Basic Impulse Level (electrical power switches) BIL Basic Insulation Level (IEC) ) (%) 1990 1.28 - 1991 1.46 13.7 1992 1.66 13.6 1993 1.86 12.4 1994 2.02 8.7 1995 2.47 22.2 1996 2.91 17.6 1997 3.51 20.8 1998 4.55 29.6 1999 5.90 29.9 2000 7.50 27.0 CAGR CAGR See: Compound Annual Growth Rate : 22.0% CONTACT: For further information please contact: Amy Arnell Kristina Menzefricke Nadge Keryhuel Mountain View London Paris (415) 961-9000 44 171 730 3438 33 1 4742 9127 (415) 961-5042(fax) 44 171 730 3343 33 1 4742 9129 REPEATS: New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of 212-575-8822 or 800-221-2462; Boston 617-330-5311 or 80 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion